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ABSTRACT
Background: Vaginal fistula (VF) is a serious medical condition characterized by an abnormal 
opening between a women’s vagina and bladder and/or rectum that results in continuous leakage 
of urine and/or stool. The knowledge base regarding the magnitude of the burden of this 
condition in sub-Saharan Africa is scarce. The aim of this study is to determine the lifetime and 
point prevalence of VF symptoms in women of reproductive age in sub-Saharan Africa.
Methods: All Demographic and Health Surveys (DHS) and Multiple Indicators Cluster Surveys 
(MICS) surveys from sub-Saharan Africa were considered. We included 19 surveys in our meta-
analyses of lifetime and point prevalence, totaling 262,100 respondents. Pooled prevalence 
estimates were obtained using Bayesian hierarchical meta-analysis models that adjusted for the 
imperfect accuracy of the survey instruments and that imputed missing observations (for point 
prevalence). 
Findings: Lifetime prevalence was estimated at 3·0 per 1,000 women of reproductive age 
(95%Credible Interval [CrI]: 1·3-5·5). After imputation of missing information, point prevalence 
was estimated at 1·0 case per 1,000 women (95%CrI: 0·3-2·4). Ethiopia has the largest number 
of women who currently experience VF symptoms.
Interpretation: This study is the first to estimate the burden of VF in 19 sub-Saharan Africa 
countries using nationally representative survey data. Point prevalence is slightly lower than 
previously estimated but these previous figures are well within the prevalence’s credible 
intervals. 
Funding: None. 
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INTRODUCTION
Vesico- or recto-vaginal fistula, hereafter referred to as vaginal fistula (VF), is a serious 
medical condition characterized by the presence of an abnormal opening (fistula) between a 
woman’s vagina and bladder and/or rectum. VF in poor resource settings usually result from 
prolonged or obstructed labor (obstetric fistula) but can also be the consequence of sexual assault 
or inadvertent injuries during surgery/operation, among other reasons. It is a highly debilitating 
condition, with women often ostracized because of the resulting constant leakage of urine and/or 
stool through the vagina 1,2. Eliminating obstetric fistula has been on the agenda of the United 
Nations Population Fund (UNFPA), through its Campaign to End Fistula, and the United States 
Agency for International Development (USAID) program for almost a decade now 3,4. 
Quantifying progress through reliable health indicators remains elusive, however. Currently, the 
burden of VF among women in sub-Saharan Africa countries is largely unknown. The most 
recent community-based estimates of prevalence, drawing data from only two African countries 
(Ethiopia and the Gambia), are of 1·60 obstetric fistulas (95% Confidence Intervals (CI): 1·16-
2·10) per 1,000 women of reproductive age 5.
Accurate estimates of the number and proportions of women suffering from this condition
are especially difficult to obtain, as it is often the case with maternal morbidity indicators 6. This 
is because the condition is rare and the affected women face considerable discrimination and 
marginalization 1,2. In a 2007 review article, Stanton et al. 6 described three types of publications 
reporting on frequency, incidence, and prevalence of obstetric fistula. The first category of papers
is mostly based on personal communications that report, without denominator, the number of 
patients treated. This is the approach used by the ‘Global Fistula Map’ 7, developed by Direct 
Relief and the Fistula Foundation in partnership with the UNFPA, which maps the worldwide 
treatment capacity for VF and the number of corrective surgery performed each year. The second 
type of publication relies on declarations made by the authors themselves, or on “surgeons’ 
estimates” but the source of data is often unclear. The third type, the least common, describes 
methods and provides appropriate denominators, albeit with varying degrees of transparency.
In sub-Saharan Africa, the two main sources of standardized nationally representative 
survey data are the USAID-sponsored DHS Program of Demographic and Health Surveys (DHS) 
and the UNICEF-sponsored Multiple Indicators Cluster Survey (MICS). In 2004, DHS started to 
include questions to estimate the prevalence of VF symptoms. However, a standardized VF 
module was only introduced after the recommendations of a 2006 expert meeting. Similarly, the 
fourth round of MICS surveys (2009-2011) included a reduced but comparable module of 
questions in a small number of countries. Some of these survey data have been used before to 
describe the scope and magnitude of the problem of VF 8-11. However, only recently have a 
sufficiently large number of standardized surveys been conducted to enable their systematic 
cross-country analysis.
Using household surveys to estimate prevalence of VF and, more generally, maternal 
morbidity is challenging, however 12,13. The survey’s questions do not have the accuracy of the 
gold standard of a gynecological examination and an imperfect specificity could greatly 
overestimate prevalence of such a rare condition 14,15. Sensitivity is not much cause for concern 
for VF since prevalence of this very rare outcome will be overwhelmingly conditioned by the 
survey instrument’s specificity. Uncertainty remains, however, about the usefulness of self-
reported VF symptoms since the validity of the DHS VF module has yet to be validated.
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The primary aim of this paper is to estimate the prevalence of VF, adjusting for the 
imperfect specificity of the women’s self-report of VF symptoms, by using all recent and 
available nationally representative surveys conducted in sub-Saharan Africa. The number of 
women currently suffering from VF symptoms is also estimated individually for each country 
with available data. Our secondary objectives are to characterize the respondents reporting VF 
symptoms and describe the profile of those who sought treatment.
METHODS
Data sources
All nationally representative DHS and MICS surveys from sub-Saharan Africa with 
available individual-data records were considered. Only surveys with questions about ‘constant 
leakage of urine or stool through vagina’ or that incorporated in a VF module in the 
questionnaire were considered (Table 1). Both DHS and MICS are face-to-face household 
surveys administered to women of reproductive age (15 to 49 years of age). A thorough overview
of these surveys has been presented elsewhere 16. Briefly, DHS and MICS are household surveys 
that use a multistage, stratified sampling method to select a nationally representative sample of 
women aged 15-49 years old, excluding homeless and institutionalized individuals. The sampling
process is generally stratified according to geographic region and/or degree of urbanization. A 
standard questionnaire is administered by trained staff to obtain information on socio-
demographic characteristics, health indicators, and, in selected countries, self-reported symptoms 
of VF.
Prevalence of vaginal fistula
The list of fistula-related questions varied by survey, but for those with the VF module, 
respondents were queried about their knowledge of fistula, presence of fistula symptoms, 
presumed cause of their fistula, whether treatment was sought, and the outcome of this treatment. 
In addition, some of the DHS surveys and all MICS surveys used a contingency question about 
fistula knowledge before asking about presence of fistula symptoms. Probes were often used, as 
well as local terms to describe the condition (e.g., maladie d’urine in francophone countries). The
complete list of probes and question for each survey, as well as the specific modules included in 
the questionnaires, can be found in the supplementary material (Tables S1 and S2). For surveys 
with a contingency question, we have assumed that, if a respondent had never heard of “a 
problem such that [a woman] experience a constant leakage of urine or stool from her vagina 
during the day and night”, this respondent has never experienced symptoms of VF.
A small number of surveys only administered the fistula questions to women who had a 
live birth in the five years before the interview, to ever pregnant women, or to ever married 
women. Since these surveys used different population denominators, they were excluded from 
our prevalence estimates. For countries with more than one survey that recorded respondents’ 
fistula symptoms, only the most recent survey was used to estimate prevalence. 
Two main prevalence estimates will be reported in this study. First, we will estimate 
lifetime prevalence of fistula symptoms. This metric reflects the proportion of respondents who 
reported having ever experienced incontinence symptoms described by the survey question as 
“uncontrollable [or constant] leakage of urine or stool from the vagina”. Second, we will 
estimate point prevalence (or current prevalence) of fistula symptoms. One survey explicitly 
asked if the women suffered from such symptoms at the time of interview (i.e., DRC DHS 2007) 
while others collected information on women who sought treatment for VF and the outcome of 
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such treatment. Only women who reported a complete remission (no more leakage of urine/stool)
are considered cured of the condition and will therefore not be included in the numerator of point 
prevalence. 
Using the 2010 population estimates from the UNDP World Population Prospects 17, we 
estimated for each country the number of women who ever experienced fistula symptoms and the
number of women who currently have VF symptoms by multiplying these prevalence estimates 
by the country-specific number of women of reproductive age.
Statistical analyses 
Prevalence
Prevalence estimates were computed for each country separately using the respondents’ 
sampling weights. These proportions were then back-transformed to the number of women 
reporting VF symptoms and rounded to the nearest integer. This pre-processing step enabled us to
take into account the respondent’s differential inclusion probabilities in the surveys. Our 
preliminary analyses have shown that clustering of observations for lifetime prevalence of VF 
symptoms could be safely ignored as the estimated intra-class correlation coefficient 18 for this 
rare outcome is extremely small (i.e., 0·004) and the average number of women surveyed per 
cluster was also small (<30).
The pooled prevalence of VF was obtained using a flexible hierarchical Bayesian 
approach that allows one to easily incorporate sources of variation into the model 19,20. To adjust 
for the imperfect nature of the survey instrument, the latent-class model described by Joseph et 
al. 21 was adapted to be used in a meta-analysis of prevalence data. The model assumes that each 
survey has its own true, but unobserved, prevalence and that the survey instruments have a 
common sensitivity and specificity. The relationship between these variables is expressed below:
P
O
= p (Se)+ (1-p )(1- Sp)
where Po is the observed prevalence (as per the survey instrument), π is the true unobserved 
prevalence of the disease, Se is the survey instrument’s sensitivity, and Sp is the instrument’s 
specificity. Since the accuracy of the DHS/MICS VF questions has never been quantified, the 
uncertainty related to the sensitivity and specificity of the survey instrument was explicitly 
incorporated into our Bayesian meta-analysis. More specifically, we used a binomial distribution 
to model the number of women reporting VF symptoms (ni). Each survey has its own prevalence 
(pi), considered here as a random variable. The logit of this variable follows a normal distribution
with mean υ and standard deviation σ. The complete model specification takes the following 
form:
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Prior distributions for model parameters and hyperparameters:
u ~ Normal(0,0.001)
s ~ Uniform(0,100)
Se ~ Uniform(0.95,1)
Sp ~ Uniform(0,0.9995)
A non-informative prior was used for the mean (υ) of the logit-transformed individual 
prevalences (μi). Further, we assumed that the individuals survey’s logit-transformed prevalence 
were drawn from a normal distribution with a standard deviation (σ) that has a non-informative 
uniform distribution. Priors for sensitivity (Se) and specificity (Sp) were elicited using uniform 
distributions. Based on subject matter knowledge, we assumed that sensitivity of the survey 
instrument would most likely fall in the 95%-100% range. For specificity, we premised that it 
would likely fall within the 0% to 99.95% range. In other words, this informative prior entails 
that we expect a minimum of 0.5 false positive per 1,000 interviewed women. (Note that using 
such a small value for the lower bound of the uniform distribution does not affect the posterior 
distribution of the prevalence estimate since a rare outcome entails that specificity cannot be 
lower than one minus the observed prevalence, see Supplemental Material.)
Among women reporting to have ever experienced VF symptoms, it was necessary to 
impute observations for a number of respondents who had missing information on whether 
treatment was sought and the outcome of this treatment. Further, five surveys recorded 
information on treatment seeking but not the outcome of this treatment. For these surveys, we 
imputed current prevalence based on the meta-analyzed proportion of successfully treated 
women. The model described above was modified to impute these responses by explicitly taking 
into account the associated uncertainty. This model is presented in more details in the 
supplementary material. 
A number of surveys recorded information on the perceived cause of VF and whether the 
respondent sought treatment for this condition and the treatment’s outcome. A hierarchical 
Bayesian meta-analysis approach was used to estimate the proportion of respondents that 
reported VF a symptoms who sought care, the proportion for which treatment resulted in 
complete remission, among women who did not seek care, the reason for not seeking treatment, 
and the self-reported cause of their VF symptoms. These meta-analyses used the same model 
specification described above, with the difference that it was not possible to adjust for imperfect 
sensitivity and specificity of the case definition since these questions were contingent on 
reporting VF symptoms. 
Models were fitted using Markov Chain Monte Carlo simulations. Estimation of the 
posterior distribution of the parameters of interest was performed using JAGS 22,23. Inferences 
were based on 200,000 iterations (an additional 50,000 iterations were used as burn-in). The 
‘rjags’ libray 24 was used to run JAGS using the R statistical software as an interface 25. The 
median of the posterior distribution and its 95% credible intervals (CrI) are reported as summary 
estimates.
Role of the funding source
The funders had no role in study design, data collection and analysis, decision to publish,
or preparation of the manuscript.
5
RESULTS
Surveys characteristics
A total of 29 population-based surveys conducted in sub-Saharan Africa included VF 
questions (Table 1). Individual-data records for the following surveys were not in the public 
domain and were therefore not included in our analyses: Equatorial Guinea (DHS 2011), Guinea-
Bissau (MICS4 2010), and Mauritania (MICS4 2011). In addition, we deemed that the 
incontinence questions of the Ivory Coast 2011-12 DHS and the Malawi 2004 DHS surveys were 
too non-specific, as they referred to general incontinence (Supplementary material, Table S1), 
which could result from a number of other conditions 26. Finally, the Mali DHS 2012-13 survey 
was also excluded because its sample was not nationally representative: almost half of the 
country’s regions were not surveyed because of the armed conflict that prevailed at that time. 
Hence, 23 surveys were considered in our analyses. Of these, we included 19 surveys in 
the meta-analysis of lifetime prevalence of VF (totaling 262,100 respondents), excluding those 
with different population denominators (Rwanda 2005 and Swaziland 2010) and only including 
the most recent survey per country (Niger 2012 and Uganda 2011). For point prevalence of VF 
symptoms, 14 surveys had information on current VF symptoms or treatment seeking and 
treatment outcome (141 responses with missing information were imputed). Point prevalence of 
the five remaining surveys that only recorded if treatment was sought was imputed based on 
overall treatment success (229 responses imputed). A map of countries with available data can be
found in Figure 1. 
Prevalence of vaginal fistulas and treatment-seeking
Lifetime prevalence of VF was estimated at 3·0 cases per 1,000 women of reproductive 
age (95%CrI: 1·3-5·5). Prevalence varied widely between countries with a low of 0·4 cases in 
Burkina Faso to a high of 19·2 cases per 1,000 women in Uganda (Figure 2). Point prevalence of 
VF symptoms is estimated at 1·0 cases per 1,000 women of reproductive age (95%CrI: 0·3-2·4) 
(Figure 3). If we replace our moderately informative prior for specificity with a completely vague
prior that uniformly covers the 0%-100% range, the estimates for lifetime prevalence increases to
3·3 per 1,000 (95% CrI: 1·4-5·9) and to 1·4 per 1,000 (95% CrI: 0·4-2·9) for point prevalence 
(see Supplementary material, Tables S3 and S4). It is highly unlikely, however, that the VF 
questions could have a perfect specificity given that daily post-partum urinary incontinence was 
found to have a prevalence of 3% in a recent review 27 and that stress urinary incontinence in 
pregnant women is common 28,29. We therefore preferred to report results from a more 
informative prior for this parameter (i.e., uniform over the 0%-99.95% range). Adjusting for the 
imperfect nature of the survey instruments improved prevalence estimates. In fact, assuming 
incorrectly a perfect sensitivity and specificity (uncorrected estimates), lifetime prevalence and 
point prevalence of VF symptoms would have been estimated at 4·4 per 1,000 (95%CrI: 2·9-6·5) 
and 2·1 per 1,000 (95%CrI: 1·2-3·3), respectively. The difference in prevalence between the 
corrected and uncorrected estimates entails that a substantial proportion of women reporting VF 
symptoms could be false positives.
Table 2 presents the respondents’ characteristics of the 23 population-based national 
surveys, stratified by respondent’s report of VF symptoms. This table shows that respondents 
reporting to have ever experienced VF symptoms are slightly older and generally reported having
had more children than the women who do not report such symptoms. There was a tendency for 
illiteracy to be associated with VF symptoms but the differences were most often not statistically 
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significant. The association between reports of VF symptoms and living in an urban area and age 
at first birth was highly variable between countries.
Using the 2010 population estimates for the number of women of reproductive age in each
of the 19 countries considered in this study, we estimated that Uganda and Ethiopia had the 
largest number of women of reproductive age who ever experienced lifetime VF symptoms with 
140,500 (95% CrI: 109,700-173,800) and 142,100 (95% CrI: 120,300-166,100) women, 
respectively (Table 3). Ethiopia also has the largest burden of VF with an estimated of 110,800 
(95% CrI: 85,500-140,100) women of reproductive age who currently experience VF symptoms.
The great majority of fistulas (81·4%) were reported to have resulted from a pregnancy, 
followed by ‘other causes’ (8·6%), pelvic operations/surgeries (4·6%), sexual assaults (3·6%), 
and ‘unknown causes’ (1·8%) (Table 4, scaled estimates; Figures S1-S5 in supplementary 
material, unscaled estimates). The proportion of fistulas that have resulted from a sexual assault 
was highest in DRC, 22%. Among the 19 surveys that recorded if treatment was sought, 70·3% 
(95%CrI: 61·2%-78·7%) of women who ever suffered from VF symptoms reported having 
sought treatment (any type) (Figure 4). A total of 13 surveys collected information on treatment 
outcome and, among women who reported having sought treatment, 74·7% (95%CrI: 69·2%-
79·9%) had a complete remission - defined as no more leakage of urine or stool (Figure 5). The 
reasons most often mentioned for not having sought treatment were costs (18·8%; 95%CrI: 
7·8%-32·4%), not knowing where to find treatment (18·3%; 95%CrI: 6·8%-32·1%), not knowing
the condition was curable (17·5%; 95%CrI: 3·7%-34·7%), and feeling too embarrassed to consult
(10·9%; 95%CrI: 6·2%-17·2%) (Table 5). 
Table 6 describes the characteristics of women who have and have not sought treatment 
for their VF symptoms. Those not reporting having sought care were generally younger and of 
lower socio-economic status. Again, the direction of association varied greatly by country.
DISCUSSION
This meta-analysis of national household surveys from sub-Saharan Africa has shown that
3·0 per 1,000 women of reproductive age (95% CrI: 1·3-5·4) had suffered from VF symptoms 
during their lifetime and that 1·0 per 1,000 women of reproductive age currently suffer from such
symptoms (95% CrI: 0·3-2·4). We estimated that Ethiopia had the largest number of women of 
reproductive age who currently experience VF symptoms (110,800), followed by Uganda 
(74,200). To the best of our knowledge, this study reports the first estimate of VF burden in sub-
Saharan Africa based on recent large-scale national survey data. Our estimated point prevalence 
of women who currently suffer from VF symptoms is consistent with the sub-Saharan Africa 
figure reported in Adler et al.’s global systematic review 5 (1·6 per 1,000 women of reproductive 
age) which were based on only two countries (Ethiopia and the Gambia). Another commonly 
used estimate of prevalence comes from the 2000 update of the Global Burden of Disease. Their 
estimate assumed that 2·15% of neglected obstructed labor would result in an VF, yielding an 
prevalence of 1·88 per 1,000 women between the ages of 15-44 years old in sub-Saharan Africa 
30. Our study shows that prevalence of VF using women’s self-reports is lower than previously 
reported, but these previous estimates are within our credible intervals. 
The great majority of women with VF symptoms reported that the cause of their fistula 
was pregnancy-related. Sexual assaults were not a common cause of VF, except in countries that 
have experienced armed conflicts such as the Democratic Republic of Congo 31,32, with 21% of 
women with VF symptoms reporting that the cause of their condition was a sexual assault. Of all 
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women reporting having experienced VF symptoms, 70·3% reported having sought any form of 
treatment. This proportion might include women seeking care through traditional healers that can 
do little when modern health system interventions are required to repair VF. Among women 
having sought care, 74·7% reported a complete remission. This proportion is consistent with the 
rate of successful surgeries reported in the fistula literature taking into account that several 
surgeries are sometimes needed for complete remission 33-35 and that a small, yet unknown, 
proportion of fistulas are deemed incurable within the challenging health system conditions and 
low resource contexts of sub-Saharan Africa 36,37. Our results suggest that costs and knowing that 
effective surgery exists (and where to get it) are the main barriers to treatment-seeking.
Despite our findings being consistent with previous studies and our understanding of the 
etiology of VF, some important limitations need to be acknowledged. Our results should be 
analyzed in view of constraints that both DHS and MICS may experience when collecting 
information on a sensitive and stigmatizing disease 16. Being household-based surveys, such data 
could underestimate prevalence if a substantial number of women with VF are homeless, 
ostracized within their own family 38, or housed in long-term care facilities dedicated to fistula 
patients 39. This should mostly affect our estimates for point prevalence, however. Second, only 
women of reproductive age were interviewed despite the facts that women older than 50 years of 
age, and those younger than 15 years of age, could also experience VF symptoms. Third, we have
assumed in our adjustments that the surveys all had a common sensitivity and specificity. This 
assumption was required to ensure model identifiability. Even if DHS and MICS surveys used a 
standardized methodology, we cannot rule out that the quality of a questionnaire’s translation in 
local languages could have resulted in different sensitivity/specificity of the VF questions. In 
addition, the respondents’ understanding of the question and familiarity with the topic of VF 
could have also varied between region and country. This could partly explain why the recorded 
prevalence in the Uganda DHS 2011 is many times higher than that of the other countries, despite
our adjustments. Excluding this latter survey from the meta-analyses only had a minor impact on 
our overall summary measures, however, with estimates of 2·8 per 1,000 (95% CrI: 1·2-4·9) and 
0·9 per 1,000 (95% CrI: 0·2-2·1) for lifetime and point prevalence, respectively. Fourth, our 
credible intervals were not adjusted for the complex survey design and this could potentially 
underestimate the sampling variance. Nonetheless, using the design-based adjustment of Korn 
and Graubard 40, which substitutes the original sample size for a degrees-of-freedom adjusted 
effective sample size, had a negligible impact on the width of the credible interval for lifetime 
prevalence of VF symptoms (this adjustment was unfortunately not possible to implement for 
point prevalence due to the imputation of missing observations). Finally, DHS/MICS data 
provides lifetime and not lifecourse information. Profile differences between women reporting 
VF symptoms and those who did not, as well as those who did and did not sought treatment, need
to be interpreted with caution. For example, the important proportion of women reporting VF 
who reside in urban in certain countries could have resulted from greater accessibility of VF 
treatment services in urban centers. Additionally, these descriptions are limited by the fact that 
the case definition likely includes a high proportion of false positives.
This study also has a number of strengths. First, our prevalence estimates are based on 19 
nationally representative surveys. Responses from 262,100 women, including 1,341 women 
reporting having ever experienced VF symptoms, were pooled. As such, we have improved on 
earlier estimates by considerably expanding the number of countries represented. We have also 
incorporated uncertainty of the survey’s instrument imperfect accuracy into our analyses, as well 
as the uncertainty in the imputation of missing observations for point prevalence through a 
8
cohesive Bayesian approach. We conducted a sensitivity analysis for the type of prior 
distributions used for sensitivity and specificity and showed that lifetime prevalence of VF is 
most likely below 3·3 per 1,000 (95%CrI: 1·4-5·9) and point prevalence below 1·4 per 1,000 
(95% CrI: 0·4-2·9).
In conclusion, this study has shown that the point prevalence of VF is slightly lower than 
previously reported. This could have resulted from the continued improvements of maternal 
health indicators in sub-Saharan Africa over the last decade 41,42 and increased availability of and 
accessibility to corrective surgery 43,44. Despite the high uncertainty related to our estimates, we 
have shown that national household surveys based on self-reports of VF symptoms can 
sometimes be used to estimate disease burden. Given the potentially high rate of false positives, 
estimates should be adjusted for the imperfect specificity of the questionnaires. 
RESEARCH IN CONTEXT
Systematic review
Vaginal fistula (VF) continues to affect the health and lives of many women in the most 
deprived parts of the world. As a public health and reproductive health right issue, VF embodies 
many of the challenges faced by the post-2015 maternal health agenda in sub-Saharan Africa 
(how to ensure timely access to emergency obstetric care, address the shortages of skilled human 
resources, improve quality of care within low-resource health systems, and maintain the rights of 
to reproductive health care during their whole life). Over the last decade, an international 
campaign has boosted fistula prevention, treatment and research. Yet, the planning and evaluation
of fistula interventions have been hampered by the lack of reliable prevalence estimates. 
We did not aim to do a comprehensive systematic review of VF prevalence as a recent 
systematic review has been conducted which identified only two robust population based studies 
in African countries5. Rather we aim to fill an evidence gap by conducting a comprehensive 
analysis of existing primary data sources. Nevertheless, we searched PubMed, Web of 
Knowledge, and Google Scholar with the Terms ("Obstetric fistula" OR "Vesico-vaginal fistula" 
OR "Vesicovaginal fistula" OR "Recto-vaginal fistula" OR "Rectovaginal fistula" OR "Genito-
urinary fistula" OR "Genitourinary fistula") AND ("Prevalence" OR "Incidence”). This search 
confirmed the lack of population based estimates on fistula in African countries, except for the 
two non-DHS studies identified by Adler et al. 5, and DHS-type data. Adler et al. 5 had rejected 
all studies based on self-reports of fistula in light of concerns over the accuracy of maternal 
morbidity questionnaires. Taking into account these concerns, we used a Bayesian approach to 
estimate the pooled prevalence from DHS/MICS surveys as this enabled us to incorporate 
uncertainty over the survey’s instrument accuracy. 
Interpretation
Overall, the lifetime prevalence of VF symptoms in sub-Saharan Africa was 3·0 per 1000 
women (95% CrI: 1·3-5·5) and the point prevalence was 1·0 per 1000 women (95% CrI: 0·3-
2·4). Ethiopia has the largest number of women who experience VF symptoms, followed by 
Uganda. The prevalence of VF using women’s self-reports is lower than previously reported, but 
these previous estimates are within our credible intervals. We have improved on earlier estimates 
by considerably expanding the number of countries represented. However, our results should be 
interpreted with caution considering the potential limitation of DHS/MICS in surveying a rare 
and ostracizing condition such as fistula. While vaginal fistula is a relatively rare event, its 
occurrence remains too frequent in African countries.
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Table 1: Availability of nationally representative surveys with vaginal fistula (VF) related
questions in sub-Saharan Africa.
Country / Survey
Individual
data record
availability
Eligibility for VF questions
(proportion of total sample
eligible)
Benin DHS 2011-12 Yes All women aged 15-49 (100%)
Burkina Faso DHS 2010 Yes All women aged 15-49 (100%)
Cameroon DHS 2011 Yes All women aged 15-49 (100%)
Chad MICS 2010 Yes With knowledge of fistula (20.3%)
Comoros DHS 2012 Yes All women aged 15-49 (100%)
Congo (Brazz.) DHS 2011-12 Yes All women aged 15-49 (100%)
DRC DHS 2007 Yes With knowledge of fistula (8.0%)
Ivory Coast DHS 2011-12* Yes All women aged 15-49 (100%)
Equatorial Guinea DHS 2011 No All women aged 15-49 (100%)
Ethiopia DHS 2005 Yes With knowledge of fistula (23.2%)
Guinea DHS 2012 Yes All women aged 15-49 (100%)
Guinea-Bissau MICS4 2010 No Ever pregnant (NA%)
Kenya DHS 2008-09 Yes All women aged 15-49 (100%)
Malawi DHS 2004* Yes All women aged 15-49 (100%)
Malawi DHS 2010 Yes All women aged 15-49 (100%)
Mali DHS 2006 Yes With knowledge of fistula (16.4%)
Mali DHS 2012-13§ Yes All women aged 15-49 (100%)
Mauritania MCIS4 2011 No
Ever married & with knowledge of
fistula (NA%)
Niger DHS 2006 Yes With knowledge of fistula (37.9%)
Niger DHS 2012 Yes With knowledge of fistula (44.1%)
Nigeria DHS 2008 Yes All women aged 15-49 (100%)
Rwanda DHS 2005 Yes Had live birth in last 5 year (47.9%)
Senegal DHS 2010-11 Yes All women aged 15-49 (100%)
Sierra Leone DHS 2013 Yes All women aged 15-49 (100%)
Swaziland MICS 2010 Yes
Ever pregnant & with knowledge of
fistula (18.8%)
Tanzania DHS 2010 Yes All women aged 15-49 (100%)
Togo MICS 2010 Yes With knowledge of fistula
Uganda DHS 2006 Yes All women aged 15-49 (100%)
Uganda DHS 2011 Yes All women aged 15-49 (100%)
VF=Vaginal Fistula; DRC=Democratic Republic of the Congo.
*Fistula module was not included but a question regarding ‘incontinence’ was asked.
§ The sample of the Mali DHS 2012-13 is not nationally representative.
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Table 2: Characteristics of respondents for each of the 23 household surveys with questions about lifetime vaginal fistula (VF) symptoms,
stratified by women’s report of VF symptoms.
Country
Sample size
(Un-weighted)
Mean age
(Years)*
Proportion
illiterate*
Proportion
living in urban
areas*
Mean
number of
children Ever
born*
Mean age
(years) at 1st
birth*¶ 
VF Not VF VF Not VF VF Not VF VF Not VF VF Not VF VF Not VF
Benin DHS 2011-12 127 16,472 28·6 28·9 70·4% 72·4% 61·6% 46·3% 2·4 2·7 20·1 20·0
Burkina Faso DHS 2010 20 17,042 33·6 28·8 57·9% 82·8% 42·9% 27·1% 3·3 3·3 19·8 19·0
Cameroon DHS 2011 56 15,363 31·0 27·9 37·6% 40·0% 68·2% 53·8% 3·2 2·7 19·5 18·8
Chad MICS 2010 40 15,817 29·1 27·8 83·6% 85·8% 45·5% 24·9% 4·1 3·9 12·9 18·4
Comoros DHS 2012 110 5,213 30·5 27·6 57·4% 46·2% 51·8% 32·8% 3·1 2·1 20·3 20·6
Congo (Brazz.) DHS 2011-12 27 10,791 30·0 28·6 25·5% 25·6% 70·8% 68·6% 2·7 2·5 17·5 19·1
DRC DHS 2007 44 9,942 30·0 28·3 38·7% 51·3% 44·5% 45·4% 4·2 3·0 18·4 19·2
Ethiopia DHS 2005 103 13,952 32·6 28·0 81·5% 78·1% 19·2% 17·7% 4·4 3·1 18·3 18·5
Guinea DHS 2012 63 9,073 30·6 28·4 81·6% 79·7% 43·5% 36·3% 3·2 3·0 18·9 18·2
Kenya DHS 2008-09 78 8,358 32·6 28·4 36·1% 26·2% 16·0% 25·5% 3·9 2·7 19·0 19·2
Malawi DHS 2010 132 22,878 29·2 28·0 51·1% 40·6% 10·7% 18·7% 3·3 3·1 19·1 18·4
Mali DHS 2006 18 14,562 34·3 28·4 100·0% 88·0% 26·8% 33·7% 5·6 3·6 19·1 18·2
Niger DHS 2006 20 9,169 28·4 28·6 95·7% 92·5% 22·2% 19·5% 3·7 4·0 18·0 17·8
Niger DHS 2012 16 11,138 28·7 28·8 100·0% 89·2% 0·0% 18·8% 4·8 4·2 16·9 18·2
Nigeria DHS 2008 142 33,175 30·8 28·7 57·2% 52·5% 30·2% 35·7% 3·6 3·1 19·0 19·4
Rwanda DHS 2005 § 164 5,222 29·1 31·3 52·0% 44·4% 9·9% 14·4% 3·7 4·2 20·7 21·1
Senegal DHS 2010-11 18 15,670 31·7 27·9 72·1% 71·1% 55·2% 49·3% 3·5 2·5 19·4 19·7
Sierra Leone DHS 2013 112 16,431 30·3 28·4 78·9% 68·5% 44·9% 35·4% 3·6 2·9 17·8 18·7
Swaziland MICS 2010 § 57 3,261 34·8 31·7 16·2% 12·3% 19·6% 30·5% 4·0 3·0 29·5 26·5
Tanzania DHS 2010 51 10,085 30·8 28·6 36·1% 33·0% 34·1% 28·5% 2·9 2·9 18·7 19·0
Togo MICS 2010 23 6,352 32·9 29·2 78·4% 57·9% 29·3% 45·3% 4·1 2·7 19·0 19·7
Uganda DHS 2006 201 8,275 30·8 28·0 60·2% 51·0% 10·7% 17·0% 4·7 3·5 18·1 18·2
Uganda DHS 2011 164 8,442 31·0 28·0 51·5% 48·5% 11·4% 19·9% 4·4 3·4 17·9 18·2
VF=Respondents reporting having ever experienced vaginal fistula symptoms; Not VF=Respondents reporting never having experienced vaginal fistula symptoms; 
DRC=Democratic Republic of Congo.
Statistical differences at the α=0·05 significance level are bolded. Significance of differences between means was assessed using design-based t-test. For proportions, we
used the χ2 statistics and the Rao-Scott adjustment for the complex survey design.
* Characteristics of respondents were adjusted using the women’s survey weight.
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¶ Excluding nulligravidae women.
§ Note that the Rwandan and Swazi surveys have different denominators: women with a live birth in preceding 5 years and ever pregnant women, respectively.
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Table 3: Estimates of the number of women of reproductive age (15-49 years of age) who ever experienced
vaginal fistula (VF) symptoms and who currently experience VF symptoms in 19 sub-Saharan countries.
Country
Number of women who ever
experienced VF symptoms
Number of women who currently
experienced VF symptoms
Median (95% CrI) Median (95% CrI)
Benin DHS 2011-12 14,600 (11,500-18,000) 9,600 (7,300-12,300)
Burkina Faso DHS 2010 1,500 (100-4,000) 500 (0-2,000)
Cameroon DHS 2011 15,500 (10,000-21,400) 1,900 (100-5,000)
Chad MICS 2010 4,900 (2,300-7,500) 800 (0-2,500)
Comoros DHS 2012 2,300 (1,800-2,900) 1,200 (900-1,700)
Congo (Brazz.) DHS 2011-12 1,600 (600-2,800) 100 (0-600)
DRC DHS 2007 25,200 (9,000-43,100) 14,200 (3,600-27,700)
Ethiopia DHS 2005 140,500 (109,700-173,800) 110,800 (85,500-140,100)
Guinea DHS 2012 13,900 (9,800-18,700) 8,300 (53,00-11,900)
Kenya DHS 2008-09 90,100 (69,400-113,700) 49,900 (34,000-69,200)
Malawi DHS 2010 16,900 (13,100-20,900) 5,200 (3,200-7,500)
Mali DHS 2006 2,300 (200-4,900) 300 (0-1,500)
Niger DHS 2012 2,800 (400-6,200) 900 (0-3,000)
Nigeria DHS 2008 115,200 (82,400-147,700) 46,800 (28,000-67,800)
Senegal DHS 2010-11 1,500 (100-3,800) 300 (0-1,400)
Sierra Leone DHS 2013 8,500 (6,600-10,600) 4,100 (2,900-5,600)
Tanzania DHS 2010 55,300 (39,400-73,400) 21,400 (10,800-34,700)
Togo MICS 2010 3,700 (1400-6,300) 1,500 (200-3,500)
Uganda DHS 2011 142,100 (120,300-166,100) 74,200 (56,000-95,700)
VF=Vaginal fistula; 95% CrI= 95% credible intervals.
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Table 4: Meta-analysis results from 15 surveys of self-reported causes of vaginal fistulas symptoms (N=889)·
Causes of vaginal
Fistulas
Number women
reporting vaginal
fistula symptoms
Percentage* 
(95% CrI)
Scaled
percentages§
Pregnancy-related 605 72·0% (59·4%-82·1%) 81·4%
Sexual assault 56 3.2% (0·7%-7·2%) 3·6%
Pelvic operation 40 4·1% (2·1%-6·5%) 4·6%
Other 68 7·6% (4·0%-13·2%) 8·6%
Does not know 124 1·6% (0·0%-9·3%) 1·8%
95%CrI=95% credible intervals
The 15 included surveys are: Benin DHS 2011-12, Burkina Faso DHS 2010, Cameroon DHS 2011, 
Comoros DHS 2012, Congo (Brazz.) DHS 2011-12, Democratic Republic of Congo DHS 2007, Guinea 
DHS 2012, Kenya DHS 2008-09, Malawi DHS 2010, Mali DHS 2006, Niger DHS 2012, Nigeria DHS 
2008, Senegal DHS 2010-11, Sierra Leone DHS 2013, Tanzania DHS 2010.
*Percentages across survey obtained through hierarchical Bayesian meta-analysis. 
§The percentages of vaginal fistulas attributable to each cause were scaled in order to sum to one.
Table 5: Meta-analysis results for mains reason women with self-reported vaginal fistulas symptoms did not seek treatment.
Reasons for not seeking care
(not mutually exclusive)
Nb. of
surveys with
response
option
Nb. not seeking
care by
reason / Total
not seeking
care
Percentage*
(95% CI)
Too Expensive 12 68/291 18·8% (7·8%-32·4%)
Does not know where to go§ 11 62/284 18·3% (6·8%-32·1%)
Thought it was not curable 12 65/291 17·5% (3·7%-34·7%)
Too Embarrassed§ 10 30/268 10·9% (6·2%-17·2%)
95%CI=95% confidence intervals
Note that the reasons for not seeking care are not mutually exclusive and that not all surveys listed 
the same response options.
*Percentage across survey obtained by random-effect meta-analysis. 
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Table 6: Characteristics of women reporting vaginal fistulas symptoms that have sought care (Tx) for this condition and those that did not
(No Tx).
Country
Sample size
(Un-weighted)
Mean age
(Years)*
Proportion
illiterate*
Proportion in
bottom quintile
of SES (poorest)*
Proportion living
in urban areas*
Tx No Tx Tx No Tx Tx No Tx Tx No Tx Tx No Tx
Benin DHS 2011-12 56 71 30·0 27·5 71·8% 69·3% 13·0% 10·5% 55·6% 66·5%
Burkina Faso DHS 2010 8 5 33·6 28·1 62·8% 35·4% 11·6% 0·0% 55·9% 52·3%
Cameroon DHS 2011 33 7 31·1 32·5 32·8% 56·6% 1·3% 20·9% 72·4% 57·2%
Chad MICS 2010 32 6 29·6 28·9 81·4% 91·8% 17·7% 23·2% 52·7% 12·5%
Comoros DHS 2012 67 33 30·9 29·4 47·0% 69·3% 12·9% 28·4% 52·7% 53·1%
Congo (Brazz.) DHS 2011-12 19 2 30·4 26·8 22·2% 0·0% 10·9% 55·0% 80·7% 45·0%
DRC DHS 2007 31 12 28·6 31·7 38·1% 55·7% 13·5% 12·4% 46·8% 58·1%
Ethiopia DHS 2005 33 67 36·1 31·2 86·8% 80·1% 18·3% 23·3% 29·1% 13·8%
Guinea DHS 2012 37 24 30·8 30·5 85·2% 74·0% 13·8% 47·8% 47·1% 33·8%
Kenya DHS 2008-09 47 31 35·6 28·6 35·8% 36·4% 10·9% 13·0% 19·3% 11·6%
Malawi DHS 2010 108 24 29·9 25·4 53·1% 39·0% 25·1% 17·9% 11·0% 8·5%
Mali DHS 2006 16 2 35·0 30·9 100·0% 100·0% 26·6% 100·0% 32·4% 0·0%
Niger DHS 2006 4 3 28·5 30·0 100·0% 100·0% 32·8% 66·7% 7·1% 0·0%
Niger DHS 2012 15 1 28·0 35·0 100·0% 100·0% 19·2% 0·0% 0·0% 0·0%
Nigeria DHS 2008 62 23 30·6 31·6 70·6% 57·4% 34·2% 18·2% 25·2% 28·5%
Rwanda DHS 2005 § 57 106 28·1 29·7 51·3% 52·8% 10·4% 25·6% 12·0% 8·8%
Senegal DHS 2010-11 12 6 30·7 35·6 68·3% 86·0% 26·4% 50·9% 60·4% 35·8%
Sierra Leone DHS 2013 68 35 31·0 28·6 76·9% 85·6% 14·1% 22·7% 46·8% 38·2%
Tanzania DHS 2010 18 6 33·1 26·5 31·5% 64·2% 21·9% 24·7% 24·7% 37·6%
Togo MICS 2010 14 9 34·1 31·2 76·5% 81·2% 5·4% 40·6% 36·4% 18·8%
Uganda DHS 2011 98 66 32·1 29·1 56·7% 42·8% 18·0% 18·5% 13·3% 8·3%
Statistical differences at the α=0·05 significance level are bolded. Significance of differences between means was assessed using design-based t-test. For proportions, we
used the χ2 statistics and the Rao-Scott adjustment for the complex survey design. 
* Women’s characteristics take into account sampling weights.
§ Note that the Rwanda DHS 2005 survey has a different denominator (i.e., women with a live birth in preceding 5 years).
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Figure legends:
Figure 1: Sub-Saharan Africa countries where nationally-representative household surveys with 
questions on vaginal fistula symptoms were conducted.
Figure 2: Lifetime prevalence of vaginal fistula symptoms per 1,000 women of reproductive age 
in sub-Saharan Africa (2005-2012).
Figure 3: Point prevalence of vaginal fistula symptoms per 1,000 women of reproductive age in 
sub-Saharan Africa (2005-2012). Countries marked with an asterisk indicate that the survey did 
not recorded information on whether the treatment for vaginal fistula symptoms was successful. 
These responses were imputed based on treatment success rate from other countries.
Figure 4: Proportion of women reporting vaginal fistula symptoms who sought care for this 
condition (2005-2012).
Figure 5: Proportion of women who reported having sought care for their vaginal fistula 
symptoms for whom the treatment resulted in complete remission (2008-2012).
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SUPPLEMENTARY ONLINE MATERIAL  
 
 This supplementary material is arranged in five sections. The first section present the incontinence questions 
and probes related to vaginal fistula (VF) symptoms from 29 household surveys conducted in sub-Saharan Africa 
(Table S1). To avoid translation errors, these questions/probes have been left in the language in which they were 
abstracted from the questionnaire (i.e., English, French, Portuguese, or Spanish). The second section details the list 
of VF-related questions, such as presumed cause of VF symptoms, treatment seeking, and treatment outcome, 
included in each survey (Table S2). The third section described the model used for imputation of missing 
observations for point prevalence. In the fourth section, the forest plots for self-reported cause of VF symptoms are 
presented (Figure S1 to S5). Finally, in the fifth section, results from the sensitivity analyses for the different prior 
specifications are presented (Tables S3 and S4). 
 
SECTION 1 
 
Table S1: Specific incontinence questions and probes related to vaginal fistula symptoms in questionnaires from 
household surveys conducted in sub-Saharan Africa (in original language). 
 
Country Probe / Contingency Question 
Benin (DHS) 
2011-12 
Les femmes peuvent parfois avoir, en permanence, le jour 
et la nuit, un problème de pertes urinaires ou fécales par le 
vagin. Ce problème survient généralement à la suite d'un 
accouchement difficile, mais il peut aussi se produire après 
une agression sexuelle ou après une opération du pelvis. 
Avez-vous déjà eu, en permanence, 
durant le jour et la nuit, des pertes 
urinaires ou fécales par le vagin? 
Burkina Faso 
(DHS) 2010 
Les femmes peuvent parfois avoir, en permanence, le jour 
et la nuit, un problème de pertes urinaires ou fécales par le 
vagin. Ce problème survient généralement à la suite d'un 
accouchement difficile, mais il peut aussi se produire après 
une agression sexuelle ou après une opération du pelvis. 
Avez-vous déjà eu, en permanence, 
durant le jour et la nuit, des pertes 
urinaires ou fécales par le vagin? 
Cameroon 
(DHS) 2011 
Une femme peut parfois avoir des écoulements constants 
d'urine où d'excréments à partir de son vagin. Ce problème 
survient généralement après un accouchement difficile, un 
viol ou une opération chirurgicale pelvienne. 
Avez-vous déjà eu un écoulement 
constant d'urine ou d'excréments à 
partir de votre vagin? 
Chad (MICS) 
2010 
Contingency: Connaissez-vous une maladie appelé fistule, 
c.-à.-d. la maladie de l’urine? 
Avez-vous déjà souffert ou souffrez-
vous actuellement de cette maladie? 
Comoros (DHS) 
2012 
Une femme peut parfois avoir des écoulements constants 
d'urine ou d'excréments à partir de son vagin. Ce problème 
survient généralement après un accouchement difficile, un 
viol ou une opération chirurgicale pelvienne. 
Avez-vous déjà eu un écoulement 
constant d'urine ou d'excréments à 
partir de votre vagin? 
Congo (DHS) 
2011-12 
Une femme peut parfois avoir des écoulements constants 
d'urine ou d'excréments à partir de son vagin. Ce problème 
survient généralement après un accouchement difficile, un 
viol ou une opération chirurgicale pelvienne. 
Avez-vous entendu parler de ce 
genre de problème, je veux dire 
d'une femme qui a des écoulements 
constants d'urine ou d'excréments à 
partir de son vagin? 
Congo DR 
(DHS) 2007 
Contingency: Connaissez-vous la maladie dénommée 
"fistule" c'est-à-dire, la maladie qui fait que la femme perd 
de l'urine et/ou défèque continuellement? 
Connaissez-vous (souffrez-vous) 
actuellement de pertes d’urines et/ou 
de selles par le vagin en dehors des 
"mictions /défécations"? 
Ivory Coast 
(DHS) 2011-12 None 
Avez-vous déjà eu des problèmes 
d'incontinence d'urine ou de selles? 
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Equatorial 
Guinea (DHS) 
2011 
Las mujeres pueden a veces tener, permanentemente, de 
día y de noche, un problema de pérdidas urinarias y/o 
fecales por la vagina. Este problema ocurre generalmente 
tras un parto difícil, pero puede también producirse 
después de una agresión/violencia sexual o después de una 
operación del pelvis. 
¿Ya tuvo usted, permanentemente, 
durante el día y la noche, de las 
pérdidas urinarias o fecales por la 
vagina? 
Ethiopia (DHS) 
2005 
Contingency: Have you ever heard of obstetric fistula (use 
local term)? If no, probe: Have you ever heard of a 
condition in which a woman continuously leaks urine 
and/or faeces following childbirth? 
Have you yourself experienced 
obstetric fistula? 
Guinea (DHS) 
2012 
Une femme peut parfois avoir des écoulements constants 
d'urine ou d'excréments à partir de son vagin. Ce problème 
survient généralement après un accouchement difficile, un 
viol ou une opération chirurgicale pelvienne. 
Avez-vous déjà eu un écoulement 
constant d'urine ou d'excréments à 
partir de votre vagin? 
Guinea-Bissau 
(MICS4) 2011 
As vezes uma mulher pode ter um probldma, depois do 
parto dificil, que ela sofre um vazamento de urina ou fezes 
na vagina durante o dia e noite. 
Já teve este problema? 
Kenya (DHS) 
2008-09 
Sometimes a woman can have a problem such that she 
experiences a constant leakage of urine or stool from her 
vagina during the day and night. This problem usually 
occurs after a difficult childbirth, but may also occur after 
a sexual assault or after a pelvic surgery. 
Have you ever experienced a 
constant leakage of urine or stool 
from your vagina during the day and 
night? 
Malawi (DHS) 
2004 
1st question: None 
Probe for 2nd question: Sometimes a woman can have a 
problem, usually after a difficult childbirth, such that she 
experiences a leakage of urine or stool from her vagina. 
1st question: After this birth, did you 
experience a problem such as: 
leakage of urine or stool from your 
vagina? 
2nd question: Have you ever 
experienced this problem? 
Malawi (DHS) 
2010 
Sometimes a woman can have a problem such that she 
experiences a constant leakage of urine or stool from her 
vagina during the day and night. This problem usually 
occurs after a difficult childbirth, but may also occur after 
a sexual assault or after a pelvic surgery. 
Have you ever experienced a 
constant leakage of urine or stool 
from your vagina during the day and 
night? 
Mali (DHS) 
2006 
Contingency: Connaissez-vous la maladie dénommée 
‘fistule’ c'est-à-dire, la ‘maladie de l’urine’? 
Avez-vous déjà contracté cette 
maladie? 
Mali (DHS) 
2012-13 
Contingency: Les femmes peuvent parfois avoir, en 
permanence, le jour et la nuit, un problème de pertes 
urinaires ou fécales par le vagin. Ce problème survient 
généralement à la suite d'un accouchement difficile, mais il 
peut aussi se produire après une agression sexuelle ou 
après une opération du pelvis. 
Avez-vous déjà eu, en permanence, 
durant le jour et la nuit, des pertes 
urinaires ou fécales par le vagin? 
Mauritania 
(MICS4) 2011 
Contingency: Connaissez-vous la maladie dénoméée 
fistule, c’est-à-dire “maladie de l’urine” survenue suite à 
un accouchement compliqué? 
Êtes-vous atteinte ou avez-vous déjà 
contractée cette maladie? 
Niger (DHS) 
2006 
Contingency: Connaissez-vous la maladie dénommée 
‘fistule’ c'est-à-dire, la ‘maladie de l’urine’? 
Êtes-vous atteinte ou avez-vous déjà 
contracté cette maladie? 
Niger (DHS) 
2012 
Contingency: Connaissez-vous la maladie dénommée 
‘fistule’ c'est-à-dire la ‘maladie de l'urine’? 
Etes-vous atteinte ou avez-vous déjà 
contracté cette maladie? 
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Nigeria (DHS) 
2008 
Sometimes a woman can have a problem such that she 
experiences a constant leakage of urine or stool from her 
vagina during the day and night. This problem usually 
occurs after a difficult childbirth, but may also occur after 
a sexual assault or after a pelvic surgery. This is called 
vesicovaginal fistula (VVF). 
Have you ever experienced a 
constant leakage of urine or stool 
from your vagina during the day and 
night? 
Rwanda (DHS) 
2005 
Sickness characterized by the incontrollable flow of urine 
and/or feces from the vagina due to a perforation in the 
wall of the vagina. 
Have you ever suffered from an 
obstetrical fistule? 
Senegal (DHS) 
2010-11 
Les femmes peuvent parfois avoir, en permanence, le jour 
et la nuit, un problème de pertes urinaires ou fécales par le 
vagin. Ce problème survient généralement à la suite d'un 
accouchement difficile, mais il peut aussi se produire après 
une agression sexuelle ou après une opération du pelvis. 
Avez-vous déjà eu, en permanence, 
durant le jour et la nuit, des pertes 
urinaires ou fécales par le vagin? 
Sierra Leone 
(DHS) 2013 
Contingency: Sometimes a women can have a problem of 
constant leakage of urine or stool from her vagina during 
the day and night. This problem usually occurs after a 
difficult childbirth, but may also occur after a sexual 
assault or after pelvic surgery. 
Have you ever experienced a 
constant leakage of urine or stool 
from your vagina during the day and 
night? 
Swaziland 
(MICS) 2010 
Contingency: Sometimes, after a difficult childbirth, a 
woman can experience a constant leakage of urine or stool 
from her vagina during the day or night. Have you ever 
heard of this problem? 
Have you ever suffered from or are 
you suffering from this condition? 
Tanzania (DHS) 
2010 
Sometimes a woman can have a problem such that she 
experiences a constant leakage of urine or stool from her 
vagina during the day and night. This problem usually 
occurs after a difficult childbirth, but may also occur after 
a sexual assault or after a pelvic surgery. 
Have you ever experienced a 
constant leakage of urine or stool 
from your vagina during the day and 
night? 
Togo (MICS) 
2010 
Contingency: Connaissez-vous une maladie appellée 
fistule vésico-vaginale? En avez-vous déjà souffert? 
Uganda (DHS) 
2006 
Sometimes a woman can have a problem, usually after a 
difficult childbirth, in which she experiences 
uncontrollable leakage of urine or stool from her vagina. 
Have you ever experienced this 
problem? 
Uganda (DHS) 
2011 
Sometimes a woman can have a problem of constant 
leakage of urine or stool from her vagina during the day 
and night. This problem usually occurs after a difficult 
childbirth, but may also occur after a sexual assault or after 
pelvic surgery. 
Have you ever experienced a 
constant leakage of urine or stool 
from your vagina during the day and 
night? 
 
 
 4 
!
SECTION 2 
!
Table S2: Availability of household surveys with questions on vaginal fistula (VF) in sub-Saharan Africa. 
 
Country Survey Type 
Heard 
of VF VF Status 
Age 
when 
VF 
Cause of 
VF 
Sought 
Treatment 
Outcome of 
Treatment 
Benin 2011-12 DHS ✓ ✓  ✓ ✓ ✓ 
Burkina Faso 2010 DHS ✓ ✓  ✓ ✓ ✓ 
Cameroon 2011 DHS ✓ ✓  ✓ ✓ ✓ 
Chad 2010 MICS4 ✓ ✓   ✓  
Comoros 2012 DHS ✓ ✓  ✓ ✓ ✓ 
Congo Brazzaville 2011-12 DHS ✓ ✓  ✓ ✓ ✓ 
DRC 2007 DHS ✓ ✓ ✓ ✓ ✓  
Cote d’Ivoire 2011-12 DHS  ✓     
Equatorial Guinea 2011 DHS ✓ ✓  ✓ ✓ ✓ 
Ethiopia 2005 DHS ✓ ✓   ✓  
Guinea 2012 DHS ✓ ✓  ✓ ✓ ✓ 
Guinea-Bissau 2010 MICS4 ✓ ✓ ✓ ✓ ✓ ✓ 
Kenya 2008-09 DHS  ✓  ✓ ✓  
Malawi 2004 DHS  ✓     
Malawi 2010 DHS ✓ ✓  ✓ ✓ ✓ 
Mali 2006 DHS  ✓  ✓ ✓ ✓ 
Mali 2012-13 DHS ✓ ✓  ✓ ✓ ✓ 
Mauritania 2011 MICS4 ✓ ✓   ✓ ✓ 
Niger 2006 DHS ✓ ✓  ✓ ✓ ✓ 
Niger 2012 DHS ✓ ✓ ✓ ✓ ✓ ✓ 
Nigeria 2008 DHS ✓ ✓  ✓ ✓ ✓ 
Rwanda 2005 DHS  ✓   ✓  
Senegal 2010-11 DHS ✓ ✓  ✓ ✓ ✓ 
Sierra Leone 2013 DHS ✓ ✓  ✓ ✓ ✓ 
Swaziland 2010 MICS4 ✓ ✓     
Tanzania 2010 DHS ✓ ✓  ✓ ✓ ✓ 
Togo 2010 MICS4 ✓ ✓   ✓  
Uganda 2006 DHS  ✓     
Uganda 2011 DHS  ✓   ✓  
 
VF=Vaginal fistula; DRC= Democratic Republic of the Congo. 
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SECTION 3 
 The Bayesian model specification for the random effect meta-analysis of point prevalence with imputation 
of missing observations takes the following form: 
(n
i
+ n*
i
) ~ Binomial( p
i
,N
i
)
p
i
= π
i
*Se+ (1−π
i
)(1− Sp)
logit(π
i
) = µ
i
µ
i
~ Normal(υ, 1
σ 2
)
 
where ni is the number of women who currently experienced VF symptoms in survey i; ni* is the imputed number of 
women who currently experienced VF symptoms; and Ni is denominator for prevalence. This remaining of this 
latent-class model specification is the same as the one described in the main paper. Imputing responses for the 
number observations with missing information on whether treatment was sought (NAsi) or whether treatment was 
successful (NAti) is done through the following equation: 
n*
i
= NAs
i
*(1−ψ
i
)+ NAs
i
*ψ
ii
*(1−φ
i
)+ NAt
i
*(1−φ
i
)  
where ψi is the country-specific proportion of women with VF symptoms who reported having sought treatment; and 
ϕi is the proportion of women who reported a complete remission after having sought treatment. These logit-
transformed survey-specific proportions (Ψi and Φi) follow a normal distribution with mean ω and standard deviation 
ο, and with mean φ and standard deviation ϑ for having sought treatment and reporting a complete remission, 
respectively. 
ns
i
~ Binomial(ψ
i
,Ns
i
)
logit(ψ
i
) =Ψ
i
Ψ
i
~ Normal(ω, 1
ο 2
)
nt
i
~ Binomial(φ
i
,Nt
i
)
logit(φ
i
) =Φ
i
Φ
i
~ Normal(ϕ , 1
ϑ 2
)
 
 It should be noted that, for the five surveys that did not recorded information on treatment outcome, nti was 
replace with the missing value indicator (i.e., ‘NA’) and the Bayesian model automatically imputed ϕi based on the 
overall distribution. The specification is completed through the following priors for the model’s parameters and 
hyperparameters: 
υ ~ Normal(0,0.001)
σ ~Uniform(0,100)
Se ~Uniform(0.95,1)
Sp ~Uniform(0,0.9995)
ω ~ Normal(0,0.001)
ϕ ~ Normal(0,0.001)
ο ~Uniform(0,100)
ϑ ~Uniform(0,100)
!
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SECTION 4 
 
 
Figure S1: Proportion of vaginal fistulas for which the presumed self-reported cause was pregnancy-related. 
 
 
Figure S2: Proportion of vaginal fistulas for which the presumed self-reported cause was a sexual assault. 
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Figure S3: Proportion of vaginal fistulas for which the presumed self-reported cause was a pelvic operation/surgery. 
 
 
Figure S4: Proportion of vaginal fistulas for which the presumed self-reported cause was any other events. 
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Figure S5: Proportion of vaginal fistulas for which the presumed self-reported cause unknown. 
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SECTION 5 
 The results from the sensitivity analyses of different prior specifications for lifetime and point prevalence of 
VF symptoms are presented in Tables S3 and S4, respectively. Priors for sensitivity (using a uniform distribution) 
were varied from a 95%-100% range to a 90%-100% and a 85%-100% range. For specificity, we varied the range 
from 0%-99.95% to a completely uninformative prior in the 0%-100% range, to a more informative prior in the 0%-
99.96% range, and to an even more informative prior in the 0%-99.94%. For this latter prior, it is implicitly assumed 
that we expect a minimum of 0.6 false positive per 1,000 interviewed women. We also included a prior for 
specificity in the 98.01%-99.95% range and 98.94%-99.95% ranges for lifetime and point prevalence, respectively, 
to show that setting the lower bound to 1 minus the maximum survey-specific observed prevalence does not impact 
our results. 
 
Table S3: Sensitivity analyses examining the impact of different prior specifications on estimates of lifetime 
prevalence of vaginal fistula symptoms. 
Prior for Sensitivity 
(Uniform) 
Prior for Specificity 
(Uniform) 
Lifetime Prevalence per 
1,000 women of 
reproductive age 
(95% CrI*) 
Priors used in the paper  
U(0·95, 1) U(0, 0·9995) 3·0 (1·3-5·5) 
Changing the prior for sensitivity  
U(0·90, 1) U(0, 0·9995) 3·1 (1·3-5·6) 
U(0·85, 1) U(0, 0·9995) 3·2 (1·4-5·8) 
Changing the prior for specificity  
U(0·95, 1) U(0, 1) 3·3 (1·4-5·9) 
U(0.95, 1) U(0, 0.9996) 3·1 (1·3-5·5) 
U(0.95, 1) U(0.9801, 0.9995) 3·0 (1·3-5·5) 
U(0·95, 1) U(0, 0·9994) 2·9 (1·2-5·4) 
 
*95% CrI=95% Credible Intervals 
 
Table S4: Sensitivity analyses examining the impact of different prior specifications on estimates of point prevalence 
of vaginal fistula symptoms. 
Prior for Sensitivity 
(Uniform) 
Prior for Specificity 
(Uniform) 
Point Prevalence per 
1,000 women of 
reproductive age 
(95% CrI*) 
Priors used in the paper  
U(0·95, 1) U(0, 0·9995) 1·0 (0·3-2·4) 
Changing the prior for sensitivity  
U(0·90, 1) U(0, 0·9995) 1·0 (0·3-2·4) 
U(0·85, 1) U(0, 0·9995) 1·0 (0·3-2·5) 
Changing the prior for specificity  
U(0·95, 1) U(0, 1) 1·4 (0·4-2·9) 
U(0·95, 1) U(0, 0·9996) 1·1 (0·3-2·5) 
U(0.95, 1) U(0.9894, 0.9995) 1·0 (0·3-2·4) 
U(0·95, 1) U(0, 0·9994) 0·9 (0·2-2·2) 
 
*95% CrI=95% Credible Intervals 
 
